α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy
Abstract
Lewy bodies in Parkinson' s disease (PD) are strongly immunoreactive with antibodies against alpha-synuclein, which is mutated in some familial cases of the disease. We carried out immunohistochemical examinations of the brains of multiple system atrophy (MSA) patients using anti-alpha-synuclein antibodies. Strong alpha-synuclein immunoreactivity was found in glial cytoplasmic inclusions (GCIs), which are of oligodendroglial origin and occur exclusively in MSA. Alpha-synuclein-immunoreactive neuronal cytoplasmic inclusions (NCIs) were also found occasionally in the substantia nigra, pontine and inferior olivary nuclei, and dentate fascia. These findings indicate that alpha-synuclein is also a major component of GCIs and NCIs in MSA and strongly suggest that alpha-synuclein aggregation is a common process in certain neurodegenerative diseases, including PD and MSA.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
MSA is characterized neuropathologically by α-syn-positive glial cytoplasmic inclusions (GCIs) in oligodendroglia.
“MSA is a synucleinopathy, however, unlike PD and dementia with Lewy bodies, in which α-syn accumulates and aggregates in neurons, MSA is characterized neuropathologically by α-syn-positive glial cytoplasmic inclusions (GCIs) in oligodendroglia [1, 42, 54, 58, 59].”
From Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates (2017) · cites this paper as [59]
The citation lists haven’t been fetched yet
References 18 · Cited by 643
- Authors
- Wakabayashi, K., Yoshimoto, M., Tsuji, S., & Takahashi, H.
- Affiliations
- Brain Research Institute, Niigata University (JP)
- Taisho Pharmaceutical (Japan) (JP)
- Corresponding author
- Wakabayashi, Koichi
- Venue
- Neuroscience Letters
- Publisher
- Elsevier BV
- Published
- 1998-06
- Volume
- 249
- Issue
- 2-3
- Pages
- 180-182
- ISSN
- 0304-3940 (ISSN-L)
- OpenAlex
- W1989999317
- Cited by
- 643
- References
- 18
- Citations by year
- 2026: 17 · 2025: 32 · 2024: 31 · 2023: 21 · 2022: 26 · 2021: 34 · 2020: 31 · 2019: 29 · 2018: 22 · 2017: 26 · 2016: 15 · 2015: 22 · 2014: 20 · 2013: 27 · 2012: 17
- FWCI
- 20.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuroscience Letters (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
- Keywords
- alpha-synuclein, glial cytoplasmic inclusions, multiple system atrophy, neuronal cytoplasmic inclusions, Lewy bodies, Parkinson's disease, oligodendroglial inclusions, alpha-synuclein aggregation, neurodegenerative diseases, substantia nigra, dentate nucleus
- MeSH terms
- Aged, Aged, 80 and over, Brain, Brain Stem, Cerebellum, Humans, Immunohistochemistry, Middle Aged, Nerve Tissue Proteins, Neuroglia, Ubiquitins, Lewy Bodies, Multiple System Atrophy, Synucleins, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
